Ascendis Pharma (ASND) Reports Positive Top-Line Results from Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency, Demonstrating Superiority on Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. META
4. DPZ
5. IBM
6. CNC
7. KFY
8. SPY
9. MU
10. ENRD

Go back to Ascendis Pharma (ASND) Reports Positive Top-Line Results from Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency, Demonstrating Superiority on Primary Endpoint

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone De

March 4, 2019 6:30 AM EST

- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH -

- Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH -

- Currently no available long-acting growth hormone treatment in the US or Europe -

- Ascendis Pharma to host conference call and webcast today at 8:00 a.m. Eastern time -

COPENHAGEN, Denmark, March 04, 2019 (GLOBE NEWSWIRE) --  Ascendis Pharma A/S (Nasdaq:... More